PMID- 36907260
OWN - NLM
STAT- MEDLINE
DCOM- 20230331
LR  - 20230331
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 946
DP  - 2023 May 5
TI  - Role of 5-HT(1A) receptors in the basolateral amygdala on 
      3,4-methylenedioxymethamphetamine-induced prosocial effects in mice.
PG  - 175653
LID - S0014-2999(23)00164-4 [pii]
LID - 10.1016/j.ejphar.2023.175653 [doi]
AB  - 3,4-methylenedioxymethamphetamine (MDMA), a recreational drug, induces euphoric 
      sensations and psychosocial effects, such as increased sociability and empathy. 
      Serotonin, also called 5-hydroxytryptamine (5-HT), is a neurotransmitter that has 
      been associated with MDMA-induced prosocial effects. However, the detailed neural 
      mechanisms remain elusive. In the present study, we investigated whether 5-HT 
      neurotransmission in the medial prefrontal cortex (mPFC) and the basolateral 
      nucleus of amygdala (BLA) is involved in MDMA-induced prosocial effects using the 
      social approach test in male ICR mice. Systemic administration of (S)-citalopram, 
      a selective 5-HT transporter inhibitor, before administration of MDMA failed to 
      suppress MDMA-induced prosocial effects. On the other hand, systemic 
      administration of the 5-HT(1A) receptor antagonist WAY100635, but not 5-HT(1B), 
      5-HT(2A), 5-HT(2C), or 5-HT(4) receptor antagonist, significantly suppressed 
      MDMA-induced prosocial effects. Furthermore, local administration of WAY100635 
      into the BLA but not into the mPFC suppressed MDMA-induced prosocial effects. 
      Consistent with this finding, intra-BLA MDMA administration significantly 
      increased sociability. Together, these results suggest that MDMA induces 
      prosocial effects through the stimulation of 5-HT(1A) receptors in the BLA.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Esaki, Hirohito
AU  - Esaki H
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
FAU - Sasaki, Yuki
AU  - Sasaki Y
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
FAU - Nishitani, Naoya
AU  - Nishitani N
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
FAU - Kamada, Hikari
AU  - Kamada H
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
FAU - Mukai, Satoko
AU  - Mukai S
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
FAU - Ohshima, Yoshitaka
AU  - Ohshima Y
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
FAU - Nakada, Sao
AU  - Nakada S
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
FAU - Ni, Xiyan
AU  - Ni X
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
FAU - Deyama, Satoshi
AU  - Deyama S
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
FAU - Kaneda, Katsuyuki
AU  - Kaneda K
AD  - Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and 
      Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan. Electronic 
      address: k-kaneda@p.kanazawa-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20230310
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - 112692-38-3 (Receptor, Serotonin, 5-HT1A)
RN  - 0 (Serotonin Antagonists)
RN  - 333DO1RDJY (Serotonin)
SB  - IM
MH  - Mice
MH  - Male
MH  - Animals
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/pharmacology
MH  - *Basolateral Nuclear Complex
MH  - Receptor, Serotonin, 5-HT1A
MH  - Mice, Inbred ICR
MH  - Serotonin Antagonists/pharmacology
MH  - Serotonin
OTO - NOTNLM
OT  - 5-HT(1A) receptors
OT  - Basolateral amygdala
OT  - MDMA
OT  - SERT
OT  - Serotonin
OT  - Sociability
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/03/13 06:00
MHDA- 2023/03/31 06:42
CRDT- 2023/03/12 20:27
PHST- 2022/12/19 00:00 [received]
PHST- 2023/02/14 00:00 [revised]
PHST- 2023/03/07 00:00 [accepted]
PHST- 2023/03/31 06:42 [medline]
PHST- 2023/03/13 06:00 [pubmed]
PHST- 2023/03/12 20:27 [entrez]
AID - S0014-2999(23)00164-4 [pii]
AID - 10.1016/j.ejphar.2023.175653 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2023 May 5;946:175653. doi: 10.1016/j.ejphar.2023.175653. Epub 
      2023 Mar 10.